Virbac confirms 2026 outlook and Virbac stock gains 2.19 percent

Published on 10/06/2026 at 12:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached EUR 768.0 million in the first half, up 7.40 percent. Virbac stock stood at EUR 314.50 on October 6, 2026, versus EUR 307.75.

Bunte Pop-Art-Comicillustration eines Tierarztes mit Hund im Labor — Pop-Art-Comicszene zeigt ein Tierarztlabor als bunte Hommage an Virbac S.A., FR0000031577, farbenfrohe Veterinärpharma-Illustration, Illustration mit AI erstellt.

Virbac (ISIN FR0000031577) was trading at EUR 314.50 at Lang & Schwarz on October 6, 2026 at 12:37 p.m. CEST, up 2.19 percent versus the prior close of EUR 307.75. The company confirmed its 2026 outlook on September 17, 2026, targeting the upper end of its 5.50 percent to 7.50 percent revenue growth range at constant exchange rates and scope.

First-half growth supports outlook

According to Virbac on September 17, 2026, revenue reached EUR 768.0 million in the first half of 2026, up 7.40 percent at constant exchange rates and scope from the first half of 2025. Companion-animal revenue increased 10.00 percent, while farm-animal revenue grew 6.70 percent.

The same release reported adjusted EBIT of EUR 144.2 million, compared with EUR 135.0 million in the first half of 2025. That represents growth of 6.80 percent, while the adjusted EBIT margin rose to 18.80 percent from 18.30 percent, a 0.50 percentage-point improvement.

Profit growth meets execution risk

Reuters reported on September 17, 2026, that Virbac attributed the performance to its Supercharge platforms and the integration of Thyronorm. Consolidated net income reached EUR 87.1 million, up 5.90 percent from the first half of 2025.

The operating picture is not cost-free. Virbac reported net debt of EUR 196.0 million at June 30, 2026, versus EUR 173.0 million at December 31, 2025, while first-half capital expenditure reached EUR 57.3 million. The company still expects a 2026 adjusted recurring operating income margin of 17.00 percent and cash generation of EUR 80.0 million.

Next sales date is October 18

The Marketscreener calendar lists October 18, 2026, for Virbac's third-quarter sales and revenue release. That date gives the market a defined checkpoint for testing whether first-half growth can carry through the second half.

Stock rises above prior close

At Lang & Schwarz, Virbac stock was trading at EUR 314.50 on October 6, 2026 at 12:37 p.m. CEST, compared with the prior close of EUR 307.75. The quote was up 2.19 percent on the session, while the primary-market 52-week range stood at EUR 297.00 to EUR 389.50 as of October 6, 2026; market capitalization was EUR 2.6 billion.

The further course of trading is shown by the continuously updated real-time quote of Virbac stock.